[SNSS] Sunesis Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 3.63 Change: 0.01 (0.28%)
Ext. hours: Change: 0 (0%)

chart SNSS

Refresh chart

Strongest Trends Summary For SNSS

SNSS is in the medium-term down -20% in 1 month and up 193% in 6 months. In the long-term down -67% below S&P in 2 years and down -77% below S&P in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company?s lead product candidate is vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia or AML. It has completed a Phase III, randomized, double-blind, placebo-controlled, and pivotal clinical trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AMl. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome. Sunesis Pharmaceuticals, Inc. has a collaboration agreement with Biogen Idec to discover, develop, and commercialize small molecule inhibitors of the human protein Raf kinase; and licensing agreeme

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -57.06% Sales Growth - Q/Q-4.69% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-90.93% ROE-223.65% ROI
Current Ratio2.59 Quick Ratio Long Term Debt/Equity Debt Ratio0.95
Gross Margin Operating Margin-976.23% Net Profit Margin-817.7% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities16.38 M Cash From Investing Activities1.54 M Cash From Operating Activities-19.81 M Gross Profit
Net Profit-8.95 M Operating Profit-10.62 M Total Assets40.74 M Total Current Assets40.72 M
Total Current Liabilities18.28 M Total Debt7.67 M Total Liabilities23.56 M Total Revenue850 K
Technical Data
High 52 week2.83 Low 52 week0.24 Last close1.17 Last change-2.5%
RSI30 Average true range0.14 Beta0.85 Volume10.39 K
Simple moving average 20 days-11.16% Simple moving average 50 days-5.5% Simple moving average 200 days-5.48%
Performance Data
Performance Week-10% Performance Month-3.31% Performance Quart121.34% Performance Half-10%
Performance Year-56.51% Performance Year-to-date181.45% Volatility daily5.93% Volatility weekly13.25%
Volatility monthly27.16% Volatility yearly94.09% Relative Volume396.47% Average Volume877.61 K
New High New Low

News

2019-06-17 08:51:12 | Options Traders Expect Huge Moves in Sunesis SNSS Stock

2019-06-15 11:30:00 | Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting

2019-06-14 08:47:08 | The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA

2019-06-08 16:09:53 | The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

2019-05-08 21:36:18 | Edited Transcript of SNSS earnings conference call or presentation 8-May-19 8:30pm GMT

2019-05-08 17:52:43 | Sunesis: 1Q Earnings Snapshot

2019-05-08 16:05:00 | Sunesis Pharmaceuticals Reports First Quarter 2019 Financial Results and Recent Highlights

2019-05-01 09:26:01 | What's in the Cards for Sunesis SNSS This Earnings Season?

2019-05-01 07:00:00 | Sunesis Pharmaceuticals to Host Conference Call on May 8th to Discuss First Quarter 2019 Financial Results and Recent Highlights

2019-04-29 16:05:00 | Sunesis Pharmaceuticals Announces Refinancing of Existing Loan with $5.5 Million Loan from Silicon Valley Bank

2019-04-04 14:35:00 | Four Healthcare Stocks Heating Up on Thursday

2019-04-03 07:00:00 | Sunesis Pharmaceuticals to Present at 18th Annual Needham & Company Healthcare Conference

2019-03-28 09:53:01 | The Zacks Analyst Blog Highlights: Roche, Celgene, Johnson and Johnson, Bayer and Sunesis Pharmaceuticals

2019-03-27 14:47:06 | 5 Cancer-Fighting Stocks to Boost Portfolio Gains

2019-03-22 13:38:00 | Edison Issues Outlook on Sunesis Pharmaceuticals SNSS

2019-03-15 08:21:12 | Will Sunesis Pharmaceuticals Continue to Surge Higher?

2019-03-07 20:40:17 | Edited Transcript of SNSS earnings conference call or presentation 7-Mar-19 9:30pm GMT

2019-03-07 16:01:00 | Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights

2019-03-04 07:00:00 | Sunesis Pharmaceuticals to Participate in Upcoming Investor Conferences

2019-03-01 10:17:03 | Puma Biotech PBYI Q4 Loss Narrows, Nerlynx Pulls Stock Up

2019-02-28 07:00:00 | Sunesis Pharmaceuticals to Host Conference Call on March 7th to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights

2019-02-15 14:25:07 | Agios AGIO Q4 Earnings Beat, Tibsovo Sales Push Up Stock

2019-02-15 10:29:03 | Acorda ACOR Q4 Earnings and Revenues Surpass Estimates

2019-01-18 07:49:06 | The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug

2019-01-17 21:58:17 | Sunesis Announces Pricing of $20 Million Offering of Securities

2019-01-17 16:05:00 | Sunesis Announces Proposed Public Offering of Common Stock and Preferred Stock

2019-01-02 07:00:00 | Sunesis Pharmaceuticals Announces Advancement into 100mg Cohort of Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies

2018-12-04 07:59:03 | The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO

2018-12-02 12:00:00 | Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at ASH Annual Meeting

2018-11-29 08:06:01 | Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals

2018-11-28 07:04:12 | 5 Top-Ranked Rising P/E Stocks to Lure Investors

2018-11-28 07:00:00 | Sunesis Pharmaceuticals to Provide Program Update for Non-Covalent BTK-Inhibitor Vecabrutinib at Analyst & Investor Event during ASH 2018

2018-11-19 07:00:00 | Sunesis Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference

2018-11-15 08:15:00 | Report: Developing Opportunities within NeuroMetrix, Sunesis Pharmaceuticals, Siga Technologies, NexPoint Residential Trust, Frequency Electronics, and Horizon Technology Finance — Future Expectations, Projections Moving into 2018

2018-11-06 07:05:10 | Edited Transcript of SNSS earnings conference call or presentation 5-Nov-18 9:30pm GMT

2018-11-05 18:28:34 | Sunesis: 3Q Earnings Snapshot

2018-11-05 16:05:00 | Sunesis Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Highlights

2018-11-01 09:17:52 | Sunesis Pharmaceuticals Announces Presentations at 60th American Society of Hematology Annual Meeting

2018-10-29 07:00:00 | Sunesis Pharmaceuticals to Host Conference Call on November 5th to Discuss Third Quarter 2018 Financial Results and Recent Highlights

2018-09-26 07:00:00 | Sunesis Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference

2018-09-12 11:56:34 | Should You Worry About The Sunesis Pharmaceuticals Inc’s NASDAQ:SNSS Shareholder Register?

2018-08-30 07:00:00 | Sunesis Pharmaceuticals to Present at the Wells Fargo Securities 2018 Healthcare Conference

2018-08-16 17:35:18 | Edited Transcript of SNSS earnings conference call or presentation 7-Aug-18 8:30pm GMT

2018-08-07 19:13:38 | Sunesis: 2Q Earnings Snapshot

2018-08-07 16:05:00 | Sunesis Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Highlights

2018-07-31 07:00:00 | Sunesis Pharmaceuticals to Host Conference Call on August 7th to Discuss Second Quarter 2018 Financial Results and Recent Highlights

2018-07-09 07:00:00 | Sunesis Pharmaceuticals Strengthens Senior Management Team

2018-06-25 16:10:00 | Sunesis Pharmaceuticals Enters into $15.5 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC

2018-06-18 07:00:00 | Sunesis Pharmaceuticals Announces Presentations at the EHA Annual Meeting

2018-06-15 09:13:01 | 5 Biotech Stocks Under $10 Worthy of Investors' Attention